



WEDNESDAY, 8th NOVEMBER 2017 COMMENCING 09:30 AM
AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | |
|---------------------------------------|------------------|
| | Enclosure |
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/1117 |

To protect commercial confidentiality the following appraisals will be held in private

- | | |
|---|----------------------------|
| 5. Appraisal 1: Full Submission (WPAS) Pegvisomant (Somavert[®]) for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated | 2/AWMSG/1117 Appendices |
| 6. Appraisal 2: Full Submission (WPAS) Levodopa-carbidopa intestinal gel (Duodopa[®]) for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results | 3/AWMSG/1117 Appendices |

The meeting will now open to the public

- | | |
|---|----------------------------|
| 7. Chairman's report (verbal update) | |
| 8. Appraisal 3: Full Submission Stiripentol (Diacomit[®]) in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate | 4/AWMSG/1117 Appendices |

Date of next meeting – Wednesday, 6th December 2017 in Cardiff